Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-YAP1 siRNA lipid nanoparticle
- Development stage
- Preclinical
- Lead developer
- University of Pennsylvania
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
anti-YAP1 siRNA lipid nanoparticle is a preclinical therapeutic candidate consisting of a small interfering RNA (siRNA) targeting Yes-associated protein 1 (YAP1) encapsulated within a lipid nanoparticle (LNP). Developed by researchers at the University of Pennsylvania, this formulation is designed to selectively target activated myofibroblasts (MFBs) in the liver. By silencing YAP1, the drug suppresses myofibroblast proliferation and induces senescence, which is a key step toward the resolution of liver fibrosis. It is being investigated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and associated liver fibrosis.
- Other names
- anti-YAP1 siRNA LNPanti-YAP-1 siRNA LNPanti-YAP 1 siRNA LNPYAP1 siRNA lipid nanoparticleYAP-1 siRNA lipid nanoparticleYAP 1 siRNA lipid nanoparticleYAP1 siRNA LNPYAP-1 siRNA LNPYAP 1 siRNA LNP
Beyond the preview
Go deeper on anti-YAP1 siRNA lipid nanoparticle.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-YAP1 siRNA lipid nanoparticle.